MannKind Corporation (MNKD)Healthcare | Biotechnology | Danbury, United States | NasdaqGM
4.04 USD
-0.05
(-1.223%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:51 a.m. EDT
The investment case here is entirely binary and hinges on the success of the Afrezza and FUROSCIX programs. While the company boasts a 'strong buy' analyst consensus and recent positive headlines regarding FDA approvals and trial data, the underlying business is currently in a precarious state. The stock has suffered a structural decline over the last nine years, dropping nearly 34% cumulatively, with the most recent annual performance showing a sharp contraction. Fundamentally, the company is burning cash with negative operating margins and a negative book value, relying on a thin cash cushion against substantial debt. The recent price action shows some resilience, trading above its 50-day moving average, which suggests short-term traders are buying the narrative of an imminent breakthrough. However, the statistical forecasting models are weak and leaning slightly negative, reflecting the uncertainty surrounding the upcoming data releases. Without a confirmed, blockbuster result from the pending trials, the current valuation appears disconnected from the reality of a loss-making biotech firm. This is a speculative play on a potential cure, not a traditional investment in a profitable enterprise. |
| Model | MAE |
|---|---|
| MSTL_97_126 ✓ | 0.130762 |
| MSTL_126 | 0.171152 |
| MSTL_97 | 0.180471 |
| AutoTheta | 0.224500 |
| MSTL | 0.224820 |
| AutoARIMA | 0.224865 |
| AutoETS | 0.224868 |
Forecast horizon: 60 days | Selected: MSTL_97_126
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 4.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.076 |
| Excess Kurtosis | -0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.309 |
| Market Cap | 1,248,158,720 |
| Forward P/E | 20.99 |
| Beta | 1.09 |
| Profit Margins | -6.63% |
| Website | https://mannkindcorp.com |
As of July 11, 2026, 4:51 a.m. EDT: Speculators are positioning for a binary event-driven catalyst rather than steady appreciation. There is heavy volume and open interest in deep out-of-the-money calls (strikes $0.50 and $1.00) expiring in late July and August, suggesting a bet on a massive gap-up driven by clinical data or regulatory approval. Conversely, there is significant put open interest at the $2.00 and $2.50 strikes, indicating a floor or a hedge against a downside scenario if the catalyst fails. The implied volatility spike on these deep strikes confirms the market is pricing in a high-risk, high-reward asymmetric payoff.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.014888287 |
| Address1 | 1 Casper Street |
| All Time High | 121.55 |
| All Time Low | 0.67 |
| Ask | 5.1 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 5,637,920 |
| Average Daily Volume3 Month | 5,690,611 |
| Average Volume | 5,690,611 |
| Average Volume10Days | 5,637,920 |
| Beta | 1.086 |
| Bid | 2.96 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | -0.192 |
| City | Danbury |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.04 |
| Current Ratio | 1.867 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.14 |
| Day Low | 3.945 |
| Display Name | MannKind |
| Dividend Date | 1,488,499,200 |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | 35,323,000 |
| Ebitda Margins | 0.09791 |
| Enterprise To Ebitda | 43.837 |
| Enterprise To Revenue | 4.292 |
| Enterprise Value | 1,548,448,640 |
| Eps Current Year | 0.085 |
| Eps Forward | 0.1925 |
| Eps Trailing Twelve Months | -0.07 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.6 |
| Fifty Day Average Change | 0.44000006 |
| Fifty Day Average Change Percent | 0.122222245 |
| Fifty Two Week Change Percent | 1.4888287 |
| Fifty Two Week High | 6.51 |
| Fifty Two Week High Change | -2.4700003 |
| Fifty Two Week High Change Percent | -0.37941632 |
| Fifty Two Week Low | 2.23 |
| Fifty Two Week Low Change | 1.81 |
| Fifty Two Week Low Change Percent | 0.81165916 |
| Fifty Two Week Range | 2.23 - 6.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,091,021,400,000 |
| Float Shares | 303,070,844 |
| Forward Eps | 0.1925 |
| Forward P E | 20.987013 |
| Free Cashflow | 47,002,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 591 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.75632006 |
| Gross Profits | 272,865,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01548 |
| Held Percent Institutions | 0.59243 |
| Implied Shares Outstanding | 308,950,166 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.mannkindcorp.com/investors-mannkind.aspx |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,488,499,200 |
| Last Split Factor | 1:5 |
| Long Business Summary | MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. |
| Long Name | MannKind Corporation |
| Market | us_market |
| Market Cap | 1,248,158,720 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_9282918 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -23,914,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,263,606,178 |
| Number Of Analyst Opinions | 8 |
| Open | 4.04 |
| Operating Cashflow | 19,267,000 |
| Operating Margins | -0.033099998 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 4.39 |
| Phone | 818 661 5000 |
| Pre Market Change | 0.03000021 |
| Pre Market Change Percent | 0.74257946 |
| Pre Market Price | 4.07 |
| Pre Market Time | 1,784,025,212 |
| Previous Close | 4.09 |
| Price Eps Current Year | 47.52941 |
| Price Hint | 4 |
| Price To Book | -21.041666 |
| Price To Sales Trailing12 Months | 3.4595828 |
| Profit Margins | -0.06628 |
| Quick Ratio | 1.428 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.0500002 |
| Regular Market Change Percent | -1.2225 |
| Regular Market Day High | 4.14 |
| Regular Market Day Low | 3.945 |
| Regular Market Day Range | 3.945 - 4.14 |
| Regular Market Open | 4.04 |
| Regular Market Previous Close | 4.09 |
| Regular Market Price | 4.04 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 4,043,370 |
| Return On Assets | 0.02031 |
| Revenue Growth | 0.151 |
| Revenue Per Share | 1.309 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 308,950,166 |
| Shares Percent Shares Out | 0.0848 |
| Shares Short | 26,186,791 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 30,330,789 |
| Short Name | MannKind Corporation |
| Short Percent Of Float | 0.0859 |
| Short Ratio | 4.97 |
| Source Interval | 15 |
| State | CT |
| Symbol | MNKD |
| Target High Price | 11.0 |
| Target Low Price | 4.75 |
| Target Mean Price | 7.59375 |
| Target Median Price | 7.0 |
| Total Cash | 133,861,000 |
| Total Cash Per Share | 0.433 |
| Total Debt | 434,151,008 |
| Total Revenue | 360,783,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.4383 |
| Two Hundred Day Average Change | -0.39830017 |
| Two Hundred Day Average Change Percent | -0.0897416 |
| Type Disp | Equity |
| Volume | 4,043,370 |
| Website | https://mannkindcorp.com |
| Zip | 6,810 |